Loading...

FITC anti-mouse CD3 Antibody

Pricing & Availability
Clone
17A2 (See other available formats)
Regulatory Status
RUO
Other Names
T cell antigen receptor complex, T3
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
17A2
C57BL/6 splenocytes stained with 17A2 FITC and 145-2C11 PE
  • 17A2
    C57BL/6 splenocytes stained with 17A2 FITC and 145-2C11 PE
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100203 50 µg $36
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100204 500 µg $143
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
γδTCR-positive T-T hybridoma D1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.

Application References

(PubMed link indicates BioLegend citation)
  1. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  2. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  2. Zhang H, et al. 2021. Front Immunol. 12:644520. PubMed
  3. Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed
  4. Lee JH, et al. 2022. EBioMedicine. 77:103903. PubMed
  5. Zhu Y, et al. 2022. Nat Commun. 13:4282. PubMed
  6. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  7. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  8. Dai L, et al. 2020. Cell. 182(3):722-733.e11. PubMed
  9. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  10. Zaman R, et al. 2021. Immunity. :. PubMed
  11. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  12. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  13. Gawish R, et al. 2022. Elife. 11:. PubMed
  14. Qiao Y, et al. 2021. Oncoimmunology. 10:1947569. PubMed
  15. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  16. Manukian G, et al. 2021. Int J Radiat Oncol Biol Phys. 110:1341. PubMed
  17. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  18. Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed
  19. Ford K, et al. 2020. Cancer Res. 80:1846. PubMed
  20. Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed
  21. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  22. Tang L, et al. 2021. Oncol Lett. 22:605. PubMed
  23. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  24. Miller CM, et al. 2020. J Virol. 94:00:00. PubMed
  25. Boyd DF, et al. 2020. Nature. 587:466. PubMed
  26. Wu X, et al. 2012. Biochem Pharmacol. 84:1164. PubMed
  27. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  28. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  29. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  30. Choi YY, et al. 2021. Cell Death Dis. 12:826. PubMed
  31. Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed
  32. Zhang S, et al. 2022. Acta Pharm Sin B. 12:3124. PubMed
  33. Steubing RD, et al. 2022. Brain Behav Immun Health. 24:100493. PubMed
  34. Mei S, et al. 2022. Front Immunol. 13:911164. PubMed
  35. Lu H, et al. 2021. Autophagy. 17:2511. PubMed
  36. Bao H, et al. 2020. Mol Med Rep. 4.675. PubMed
  37. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  38. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  39. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  40. Chou YJ, et al. 2020. Sci Rep. 10:8422. PubMed
  41. Bromley SK, et al. 2020. Cell Reports. 32(9):108085. PubMed
  42. Diao L, et al. 2022. iScience. 25:105511. PubMed
  43. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  44. Huang Y, et al. 2021. Radiother Oncol. 162:34. PubMed
  45. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
  46. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  47. Tan X, et al. 2021. Front Oncol. 11:768222. PubMed
  48. Oliva Chávez AS, et al. 2021. Nat Commun. 12:3696. PubMed
  49. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  50. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  51. Sun CC, et al. 2020. Genome Med. 0.553472222. PubMed
  52. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  53. Dolgova EV, et al. 2022. Int J Mol Sci. 23:. PubMed
  54. Mostafavi H, et al. 2022. PLoS Pathog. 18:e1010185. PubMed
  55. Sala D, et al. 2022. Mol Ther Methods Clin Dev. 25:170. PubMed
  56. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  57. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  58. Davis FM, et al. 2019. Arterioscler Thromb Vasc Biol. 39:2353. PubMed
  59. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  60. Lesmeister M, et al. 2005. Reprod Biol Endocrinol. 29:74. PubMed
  61. Deng P, et al. 2022. Cells. 11:. PubMed
  62. Li Y, et al. 2022. Clin Transl Immunology. 11:e1362. PubMed
  63. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  64. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  65. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  66. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  67. White C, et al. 2014. J Immunol. 193:5933. PubMed
  68. Chen Y, et al. 2012. PLoS One. 7:e47190. PubMed
  69. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  70. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  71. Dang Y, et al. 2022. Cancer Cell Int. 22:88. PubMed
  72. Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed
  73. Geng T, et al. 2022. Methods Mol Biol. 2585:71. PubMed
  74. Lee M, et al. 2014. PLoS One. 9:112666. PubMed
  75. Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed
  76. Solanki A, et al. 2018. Development. 145. PubMed
  77. Shields BD, et al. 2019. Cancer Res. 79:1113. PubMed
  78. Carr RM, et al. 2021. Nat Commun. 12:2901. PubMed
  79. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  80. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
  81. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  82. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  83. Kimball AS et al. 2019. Immunity. 51(2):258-271 . PubMed
  84. Naing A et al. 2019. Cell reports. 26(5):1242-1257 . PubMed
  85. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  86. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  87. Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed
  88. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  89. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  90. Chen Q, et al. 2016. Nat Commun. 7:13193. PubMed
  91. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  92. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  93. Omori S, et al. 2021. Cell Reports. 34(6):108734. PubMed
  94. Wang X, et al. 2018. Mol Med Rep. 17:1660. PubMed
  95. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  96. Comazzetto S et al. 2018. Cell stem cell. 24(3):477-486 . PubMed
  97. Ding Y, et al. 2022. Cell Death Dis. 13:996. PubMed
  98. Tang X, et al. 2022. Cell Rep. 41:111673. PubMed
  99. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  100. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  101. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  102. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  103. Harnett MM, et al. 2022. Front Immunol. 13:953053. PubMed
  104. Koren E, et al. 2022. Nat Commun. 13:4628. PubMed
  105. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  106. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  107. Ye P, et al. 2022. Front Cardiovasc Med. 8:810477. PubMed
  108. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  109. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  110. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  111. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  112. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  113. Akhter N, et al. 2016. J Biol Chem. 291: 23672 - 23680. PubMed
  114. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
  115. Markey K, et al. 2014. J Immunol. 192:5426. PubMed
  116. Sreekumar PG, et al. 2018. J Control Release. 283:94. PubMed
  117. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  118. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  119. Xu X, et al. 2018. Cell. 175:1336. PubMed
  120. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  121. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  122. Liu W, et al. 2021. Cell Death Discov. 7:136. PubMed
  123. França TT, et al. 2021. JCI Insight. 6:. PubMed
  124. Carbone C, et al. 2021. J Immunother Cancer. 9:. PubMed
  125. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  126. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  127. Du J, et al. 2012. Stem Cells. 30:1447. PubMed
  128. Weinheimer-Haus E, et al. 2014. PLoS One. 9:91355. PubMed
  129. Zheng L, et al. 2020. Front Oncol. 10:531131. PubMed
  130. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  131. Moon HG et al. 2018. Immunity. 49(2):275-287 . PubMed
  132. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  133. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  134. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  135. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  136. Port JR, et al. 2020. J Virol. 94:. PubMed
  137. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  138. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  139. Alsina-Sanchis E, et al. 2020. Mol Cancer Res. . PubMed
  140. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  141. Choi EW, et al. 2020. Sci Rep. 10:12001. PubMed
  142. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  143. Cohen M et al. 2018. Cell. 175(4):1031-1044 . PubMed
  144. Ma W, et al. 2017. Cell Death & Disease. 10.1038/cddis.2017.47. PubMed
  145. Yu H, et al. 2021. Front Oncol. 11:736882. PubMed
  146. Xiao Y, et al. 2022. Nat Commun. 13:758. PubMed
  147. Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed
  148. Ali S, et al. 2021. PLoS One. 16:e0246646. PubMed
  149. Yang Z, et al. 2021. Nat Commun. 12:4852. PubMed
  150. Pandit M, et al. 2021. Eur J Immunol. 51:1461. PubMed
  151. Lingegowda H, et al. 2022. Front Reprod Health. 3:726936. PubMed
  152. Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
  153. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  154. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  155. Yi H, et al. 2021. Front Immunol. 12:719189. PubMed
  156. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  157. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  158. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  159. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  160. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  161. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  162. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  163. Wang Z, et al. 2021. Acta Pharm Sin B. 694:11. PubMed
  164. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  165. Wu L, et al. 2020. Cell Rep. 33:108327. PubMed
  166. Zan H, et al. 2017. Nat Commun. 8:14244. PubMed
  167. Cabrera-Perez J, et al. 2016. J Immunol. 197: 1692 - 1698. PubMed
  168. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  169. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  170. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  171. Roy S, et al. 2019. Front Immunol. 2.404166667. PubMed
  172. Scally S, et al. 2017. Nat Commun. . 10.1038/s41467-017-01924-3. PubMed
  173. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  174. Smith-Díaz CC, et al. 2021. Front Oncol. 11:709543. PubMed
  175. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  176. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  177. Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed
  178. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  179. Li M, et al. 2021. Br J Pharmacol. 178:2617. PubMed
  180. Yang YS, et al. 2022. Nat Commun. 13:6175. PubMed
  181. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  182. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  183. Nam J, et al. 2021. Adv Ther (Weinh). 4:. PubMed
  184. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  185. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  186. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  187. van den Berk P, et al. 2020. Cell Rep. 33:108533. PubMed
  188. Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed
  189. Campolo M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  190. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  191. Chen C, et al. 2020. Front Cell Neurosci. 14:8. PubMed
  192. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  193. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  194. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  195. Fujimoto M, et al. 2022. Nat Commun. 13:5408. PubMed
  196. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  197. Ravindran Menon D, et al. 2021. Pharmaceuticals (Basel). 14:. PubMed
  198. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
  199. Aulova KS, et al. 2022. Molecules. 27:. PubMed
  200. Yang N, et al. 2022. Nat Commun. 13:2336. PubMed
  201. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  202. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  203. Jia H, et al. 2018. Int J Oncol. 53:949. PubMed
  204. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  205. Tao Z, et al. 2022. Cells. 11:. PubMed
  206. Tang T, et al. 2022. J Immunother Cancer. 10:. PubMed
  207. Zhou Y, et al. 2022. Theranostics. 12:5488. PubMed
  208. Chen LH, et al. 2021. Sci Rep. 11:19478. PubMed
  209. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  210. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  211. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  212. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  213. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  214. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  215. Pan X, et al. 2019. BMC Complement Altern Med. 19:163. PubMed
  216. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  217. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  218. Zukauskas A, et al. 2018. mSphere. 3:e00303. PubMed
  219. Mincham KT, et al. 2021. Front Immunol. 11:601494. PubMed
  220. Zheng Y, et al. 2022. Transl Res. :. PubMed
  221. Gawish R, et al. 2022. Elife. 11:. PubMed
  222. Li J, et al. 2022. Nat Commun. 13:1481. PubMed
  223. Roberto MP, et al. 2021. Immunity. 54(8):1807-1824.e14. PubMed
  224. Goldberg EL, et al. 2021. Cell Metabolism. :. PubMed
  225. Tanegashima K et al. 2017. EBioMedicine. 24:247-256 . PubMed
  226. Crowe J, et al. 2020. PLoS Pathog. 16:e1008391. PubMed
  227. Tur J, et al. 2020. Cell Reports. 32(8):108079. PubMed
  228. Sun Q, et al. 2022. J Inflamm Res. 15:5827. PubMed
  229. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  230. Li C, et al. 2022. Front Cell Dev Biol. 10:913824. PubMed
  231. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  232. Pastor Arroyo EM, et al. 2022. Clin Sci (Lond). 136:557. PubMed
  233. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  234. Zhang J, et al. 2021. Stem Cell Res Ther. 12:579. PubMed
  235. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  236. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
  237. Zheng QY, et al. 2020. FASEB J. 34:10590. PubMed
  238. Li J, et al. 2021. eLife. 10:00. PubMed
  239. Trivedi S, et al. 2020. Elife. 9:00. PubMed
  240. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  241. Fan X, et al. 2014. PLoS One. 9:107638. PubMed
  242. Martínez-Vicente P, et al. 2019. PLoS Pathog. 15:e1007658. PubMed
  243. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  244. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
RRID
AB_312660 (BioLegend Cat. No. 100203)
AB_312661 (BioLegend Cat. No. 100204)

Antigen Details

Structure
Ig superfamily, CD3/TCR, 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
Antigen recognition, TCR signal transduction, T cell activation
Ligand/Receptor
Peptide antigen/MHC-complex
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12502 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Other Formats

View All CD3 Reagents Request Custom Conjugation
Description Clone Applications
FITC anti-mouse CD3 17A2 FC
PE anti-mouse CD3 17A2 FC
Purified anti-mouse CD3 17A2 FC,IHC-F,IP,ICC
Alexa Fluor® 647 anti-mouse CD3 17A2 FC,IHC-F,3D IHC,SB
Alexa Fluor® 488 anti-mouse CD3 17A2 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse CD3 17A2 FC
Alexa Fluor® 700 anti-mouse CD3 17A2 FC
PerCP/Cyanine5.5 anti-mouse CD3 17A2 FC
PE/Cyanine7 anti-mouse CD3 17A2 FC
APC/Cyanine7 anti-mouse CD3 17A2 FC
Brilliant Violet 421™ anti-mouse CD3 17A2 FC,ICC
Brilliant Violet 570™ anti-mouse CD3 17A2 FC
Brilliant Violet 650™ anti-mouse CD3 17A2 FC
Brilliant Violet 785™ anti-mouse CD3 17A2 FC
Brilliant Violet 510™ anti-mouse CD3 17A2 FC
APC anti-mouse CD3 17A2 FC
Ultra-LEAF™ Purified anti-mouse CD3 17A2 FC,IHC-F,IP,ICC
Brilliant Violet 605™ anti-mouse CD3 17A2 FC
Alexa Fluor® 594 anti-mouse CD3 17A2 IHC-F,FC,3D IHC,SB
Brilliant Violet 711™ anti-mouse CD3 17A2 FC
Biotin anti-mouse CD3 17A2 FC,IHC-F
PE/Dazzle™ 594 anti-mouse CD3 17A2 FC
APC/Fire™ 750 anti-mouse CD3 17A2 FC
Brilliant Violet 750™ anti-mouse CD3 17A2 FC
TotalSeq™-A0182 anti-mouse CD3 17A2 PG
TotalSeq™-B0182 anti-mouse CD3 17A2 PG
Spark Blue™ 550 anti-mouse CD3 17A2 FC
Spark NIR™ 685 anti-mouse CD3 17A2 FC
TotalSeq™-C0182 anti-mouse CD3 17A2 PG
APC/Fire™ 810 anti-mouse CD3 17A2 FC
PE/Fire™ 640 anti-mouse CD3 17A2 FC
Spark YG™ 570 anti-mouse CD3 17A2 IHC-F
PE/Fire™ 700 anti-mouse CD3 17A2 FC
PE/Cyanine5 anti-mouse CD3 17A2 FC
Spark Blue™ 574 anti-mouse CD3 Antibody 17A2 FC
Spark Violet™ 423 anti-mouse CD3 17A2 FC
PE/Fire™ 810 anti-mouse CD3 17A2 FC
Spark Red™ 718 anti-mouse CD3 17A2 FC
Spark UV™ 387 anti-mouse CD3 17A2 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account